Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENGPHARMACEUTICALCO., LTD.
Securities code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) securities abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Announcement No.: 2022036
Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Announcement on the resolution of the fifth interim meeting of the Fifth Board of directors in 2022
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as “the company”) the Fifth Board of directors
The fifth interim meeting of the board of directors in 2022 voted by communication on March 7, 2022
Held in style. The Securities Department of the company has sent e-mail, wechat
Notify all directors by telephone. The meeting was convened by Ms. Zhou Xiaoli, the chairman of the board of directors. There were 6 directors who should attend the meeting and 6 directors who actually attended the meeting. The number of voting participants and the convening and convening procedures of this meeting comply with the relevant provisions of the company law and the articles of association, and the meeting is legal and effective. The meeting considered and adopted the following proposals:
1、 Notice on Exemption of the fifth interim meeting of the Fifth Board of directors in 2022
Limited motion
After deliberation and voting by the directors attending the meeting, it was agreed to waive the notice period of the fifth interim meeting of the Fifth Board of directors in 2022, and no meeting notice was given three days in advance. It was decided to 2022
On March 7, 2022, the fifth interim meeting of the Fifth Board of directors was held.
Voting status of the proposal: 6 in favor, 0 against, 0 abstention, passed
Yes.
2、 Discussion on the company’s plan for non-public offering of shares in 2022 (Revised Draft)
case
See the details of this proposal on the website of Shanghai Stock Exchange (www.sse. Com. CN.) on the date of disclosure of this announcement Company Announcement No. 2022038 published.
The voting result of the proposal: 5 in favor, 0 against, 0 abstention, passed
Yes. Ms. Zhou Xiaoli, a related director, avoided voting.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENGPHARMACEUTICALCO., LTD.
Among the above proposals, the independent directors of the company expressed independent opinions on the second proposal,
For details, see the website of Shanghai Stock Exchange on the date of disclosure of this announcement
（www.sse.com.cn.） Relevant contents published.
It is hereby announced
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) board of directors
March 7, 2022
